Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 159 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: PCV Clear all
Completed Not applicable Interventional

Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs

NCT00257127
View directory record Official record
Conditions
HIV Infections
Interventions
Pneumococcal 7-valent conjugate vaccine, Pneumococcal polysaccharide vaccine, Hepatitis B vaccine, Measles, mumps, and rubella virus vaccine, live
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 23 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
24
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

NCT01852591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT01351896
View directory record Official record
Conditions
Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Pneumococcal Polyvalent Vaccine
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 79 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed No phase listed Observational

Erythropoietin Resistance in Anemia of Chronic Kidney Disease

NCT00526747
View directory record Official record
Conditions
Anemia, Kidney Failure, Erythropoietin
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

NIRS Guidance Trail in Children's Heart Surgery

NCT02157597
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
NIRS based management, Control
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 6 Months
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or With Omeprazole 80 mg 12 Hours Apart in Healthy Subjects

NCT01129388
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, Placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Sep 2, 2026, 10:29 PM EDT
Not yet recruiting Not applicable Interventional

Circadian Light Exposure Adjustment for Restfulness

NCT07391852
View directory record Official record
Conditions
Sleep Onset Latency
Interventions
Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
Device
Lead sponsor
University of Arizona
Other
Eligibility
60 Months to 83 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Results available

Microfragmented Adipose Tissue Versus Platelet-rich Plasma for Knee Osteoarthritis: a Randomized Comparative Trial

NCT04351087
View directory record Official record
Conditions
Osteoarthritis, Knee, Microfragmented Adipose Tissue, Platelet-Rich Plasma
Interventions
Platelet Rich Plasma
Device
Lead sponsor
Ohio State University
Other
Eligibility
25 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
Interventions
Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera assay
Biological · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Orlando, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed No phase listed Observational

Monitoring Outpatient Blood VolumE in Heart Failure

NCT04660396
View directory record Official record
Conditions
Heart Failure
Interventions
BVA-100
Device
Lead sponsor
Daxor Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31 valent pneumococcal conjugate vaccine, PCV20, PCV21
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
30
States / cities
Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

NCT00005796
View directory record Official record
Conditions
Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions
filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation
Procedure · Biological · Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 2, 2026, 10:29 PM EDT
Terminated Not applicable Interventional

Standard Total Knee Arthroplasty Using Platelet Rich Plasma (PRP)

NCT01075230
View directory record Official record
Conditions
Osteoarthritis
Interventions
Total knee arthroplasty
Procedure
Lead sponsor
Exactech
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
42
States / cities
Jonesboro, Arkansas • Los Angeles, California • Miami, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

NCT06550011
View directory record Official record
Conditions
Neovascular (Wet) AMD
Interventions
ABI-110 Low Dose, ABI-110 Medium Dose, ABI-110 High Dose
Drug
Lead sponsor
Avirmax Biopharma Inc
Industry
Eligibility
50 Years to 89 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
4
States / cities
Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04618744
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis
Interventions
ORMD-0801 (Insulin) capsule 8 mg BD, Placebo
Drug · Other
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Sep 2, 2026, 10:29 PM EDT
Completed No phase listed Observational Results available

The Effect of Hypotensive Anesthesia on Hemoglobin Levels During Total Knee Arthroplasty

NCT05340751
View directory record Official record
Conditions
Anesthesia
Interventions
Blood drawn
Diagnostic Test
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
40 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of FrontlineODP™ Spray Dried Plasma

NCT05629338
View directory record Official record
Conditions
Coagulopathy, Hemorrhage
Interventions
Autologous Spray Dried Plasma
Combination Product
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
3
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Sep 2, 2026, 10:29 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis

NCT02872142
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Albutein 5%, Plasma Exchange
Biological · Procedure
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
19 Years to 69 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

NCT01656759
View directory record Official record
Conditions
Osteoarthritis, Intraoperative Bleeding
Interventions
Evicel Fibrin Spray
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Oak Park, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Not applicable Interventional

Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas

NCT01653834
View directory record Official record
Conditions
Glioblastoma
Interventions
Lymphocyte harvesting & reinfusion
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 2, 2026, 10:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt

NCT06282458
View directory record Official record
Conditions
Muscle Loss, Obesity
Interventions
Enobosarm, Semaglutide
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
60 Years to 100 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
14
States / cities
Anniston, Alabama • Cullman, Alabama • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 2, 2026, 10:29 PM EDT